Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YWHAG | P61981 | 1/20 | 0.53 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31741653 | 0.88 | YWHAG (0.68) | YWHAGCYP4Z1SMN1; SMN2NFKB1PKM | |
| SCHEMBL4140693 | 0.88 | YWHAG (0.68) | YWHAGCYP4Z1SMN1; SMN2NFKB1PKM | |
| SCHEMBL3649411 | 0.86 | ESR1 (0.53) | YWHAGCYP4Z1SMN1; SMN2NFKB1PKM | |
| SCHEMBL13492095 | 0.86 | MEN1 (0.49) | YWHAGCYP4Z1SMN1; SMN2NFKB1PKM | |
| SCHEMBL3204861 | 0.85 | YWHAG (0.51) | YWHAGCYP4Z1SMN1; SMN2NFKB1PKM | |
| SCHEMBL334348 | 0.84 | GAA (0.63) | YWHAGSMN1; SMN2NFKB1PKMNPC1 | |
| SCHEMBL17689712 | 0.83 | YWHAG (0.50) | YWHAGCYP4Z1SMN1; SMN2NFKB1PKM | |
| SCHEMBL16319014 | 0.83 | CYP4F2 (0.61) | YWHAGCYP4Z1GAAALDH1A1CYP4F2 | |
| SCHEMBL4029467 | 0.83 | GAA (0.54) | YWHAGCYP4Z1SMN1; SMN2NFKB1PKM | |
| SCHEMBL137925 | 0.83 | YWHAG (0.50) | YWHAGCYP4Z1SMN1; SMN2NFKB1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-2268141-B1 | COMPOUND AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2488020-B1 | 3-SUBSTITUTED COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-1608633-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| EP-1608633-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-9115072-B2 | Compounds and method for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-08-25 | — | — | US | disclosed |
| CN-101969773-B | compounds and methods for reducing uric acid | WELLSTAT THERAPEUTICS CORP. (US) | 2015-08-19 | — | — | CN | disclosed |
| CN-102976928-B | Compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORP | 2014-09-17 | — | — | CN | disclosed |
| CN-102573462-B | Compounds substituted in position 3 for reducing uric acid | WELLSTAT THERAPEUTICS CORP | 2014-04-16 | — | — | CN | disclosed |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-03 | — | — | US | disclosed |
| CN-1759104-A | Non-nucleoside reverse transcriptase inhibitors I for the treatment of HIV mediated diseases | HOFFMANN LA ROCHE (CH) | 2006-04-12 | — | — | CN | disclosed |
| EP-1608633-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES | F. Hoffmann-La Roche AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| EP-1608629-A1 | BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005102989-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
| US-20050239880-A1 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-10-07 | — | — | US | disclosed |
| WO-2004085411-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004085406-A1 | BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192704-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239880-A1 | Methods for treating retroviral infections | CCR5, CD38, CD4 | YWHAG 2502/4885CYP4Z1 2750/4885SMN1; SMN2 1944/4885 |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | RCC2, HAX1, SLC10A6 | YWHAG 2230/4885CYP4Z1 2429/4885SMN1; SMN2 1128/4885 |
| US-20040192704-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR1A, POLA1, REV1 | YWHAG 3478/4885CYP4Z1 769/4885SMN1; SMN2 1062/4885 |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR1A, POLR2A, POLR2E | YWHAG 4289/4885CYP4Z1 592/4885SMN1; SMN2 1790/4885 |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | RPP30, PNP, RTF1 | YWHAG 2427/4885CYP4Z1 3392/4885SMN1; SMN2 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.